The growth of Viagra and its effect on the medicinal landscape presents a complicated question for investors. While the first sales statistics were impressive, the exclusivity has ended, leading to a flood of off-brand alternatives that are chipping away at profit. Moreover, the industry is facing difficulties related to population trends and evolv